This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Since 1983, when the teratogenicity of isotretinoin was first documented in humans,¹ the Dermatologic and Ophthalmic Drugs Advisory Committee of the US Food and Drug Administration (FDA) has met frequently to make recommendations to balance the needs of patients with severe cystic acne to receive isotretinoin with the need to protect fetuses from exposure.² Central to these efforts has been a sponsor-developed pregnancy prevention program (PPP). Unfortunately there has been suboptimal participation in the PPP, and noncompliance with aspects of the program has been documented.² Most importantly, pregnancies have continued to occur in women receiving this drug. In fact, since the drug was approved in 1982, the sponsor has documented 1995 isotretinoin-exposed pregnancies–clearly this is an underrepresentation of the total number of exposed pregnancies as the enrollment in the PPP has been low.² On September 18, 2000, the FDA's Advisory Committee recommended new restrictions on prescribing and . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?